Q-omics provides the consensus-scored INPP5E profile across patient tissues and cancer cell-line models. INPP5E expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, INPP5E is differentially expressed in 12, with the highest sampling consensus in COAD. Additionally, INPP5E RNA expression shows 20,312 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and COAD as cancer lineages where INPP5E shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for INPP5E — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes INPP5E survival associations across molecular data types. INPP5E RNA expression shows survival associations in the most cancer types (23), followed by mutation status (6) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible INPP5E RNA expression–survival associations across cancer types. High INPP5E expression shows unfavorable associations in ACC, KIRC, UVM, LGG, COAD and MESO. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for INPP5E RNA expression.
This table summarizes INPP5E tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 2. The strongest signals are observed in COAD for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for INPP5E. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. INPP5E shows higher tumor expression in COAD, HNSC, LIHC, STAD, CHOL and READ. The COAD box plot shows higher INPP5E RNA expression in tumor versus normal tissue (log2 FC = +1.165, t-test p < 0.001).
This table shows molecular features associated with INPP5E in patient tissues and cancer cell lines. In patient samples, INPP5E shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, INPP5E RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BLOOD_Leukemia.
